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Investigations into the mechanism of hyperkalemia following renal
transplantation. Hyperkalemia was observed in 23 of 75 patients in
the first three months following renal transplantation. The hyper-
kalemia was unrelated to rejection, renal failure, oliguria, or
acidosis. Six patients (four with hyperkalemia and two with normal
serum potassium) were studied to evaluate the role of the renin-
angiotensin-aldosterone system and/or impairment of renal tubu-
lar potassium handling in this syndrome. Following equilibration
on a normal dietary intake, patients were placed on a low sodium
diet and were given furosemide. All patients achieved sodium and
potassium balance during both periods, but at the expense of
significant hyperkalemia (5.3 to 5.7 mEq/liter) in the four patients
with preexisting hyperkalemia. Plasma aldosterone concentration
and urinary aldosterone excretion rates in the hyperkalemic
patients were 8.4 0.6 ng/dl and 2.8 + 1.1 sg/day, respectively,
on a control diet, and they rose appropriately to 15.4 1.9 ng/dl
and 20.3 + 1.4 tg/day with sodium restriction. Subsequent admin-
istration of exogenous mineralocorticoid, 9-a fluorohydrocorti-
sone (Florinef), I mg/day, while the sodium intake was high, failed
to increase urinary potassium excretion. Neither furosemide nor
acetazolamide plus sodium bicarbonate administration produced a
consistent increase in potassium excretion despite a significant
natriuresis. In contrast, hydrochlorothiazide increased urinary po-
tassium excretion in three patients from 34 8 mEq/day to 54 5
mEq/day, and serum potassium concentrations fell to normal in
all. Three patients, restudied when the serum potassium concentra-
tions were normal, had kaliuretic responses to 9-a fluorohydro-
cortisone and furosemide. These data demonstrate a reversible
defect in urinary potassium excretion following renal trans-
plantation. The impaired response to mineralocorticoids suggests
that this defect is related to an abnormality of renal tubular func-
tion. The mechanism of correction with thiazides in unknown.
Etude des mécanismes de l'hyperkaliémie consecutive il Ia trans-
plantation rénale. Une hyperkaliémie a été observée chez 23 parmi
75 malades dans les trois premiers mois consécutifs a une trans-
plantation rénale. L'hyperkaliémie n'était pas en rapport avec un
rejet, une insuffisance rénale, une oligurie ou une acidose. Six
malades (quatre atteints d'hyperkaliémie et deux dont le potassium
plasmatique était normal) ont été étudiés afin d'évaluer le role du
système rénine-angiotensine-aldostérone et/ou l'altération du
comportement tubulaire vis-à-vis du potassium dans ce syndrome.
Après one période d'equilibration avec one alimentation normale
les sujets ont recu un régime pauvre en sodium et de Ia furosémide.
Tous le sujets ont atteint un état stationnaire au cours des deux
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périodes, mais au prix d'une hyperkaliémie significative (5,3 a 5,7
mEq/liter) chez les quatre d'entre eux qui avaient one hyperka-
liémie antérieure. La concentration plasmatique d'aldostérone et
les debits d'excrétion urinaire d'aldostérone chez les quatre sujets
hyperkaliemiques étaient de 8,4 ng/dl et 2,8 1,1 12g/jour
respectivement avec Ic régime de Ia période contrôle et ont aug-
menté de facon adequate a 15,4 1,9 ng/dl et 20,3 l,4sg/jour
au cours de Ia restriction de sodium. L'administration ultérieure de
minéralo-corticoldes exogènes, 9 a -fluorohydrocortisone (Flori-
nef) I mg/jour, alors que l'apport de sodium était élevé n'a pas
augmenté l'excrétion urinaire de potassium. Ni l'administration de
furosémide ni celle d'acetazolamide associée a do bicarbonate
n'ont produit une augmentation importante de l'excrétion du po-
tassium malgré une natriurése significative. L'hydrochlorothiazide,
au contraire, a augmenté l'excrétion orinaire de potassium chez
trois sujets de 34 8 mEq/jour a 54 5 mEq/jour et le potassium
plasmatique est revenu a Ia normale chez tous. Trois sujets, éto-
dies nouveau alors que leur potassium plasmatique était revenu
a Ia normale, avaient one réponse kaliurCtique a Ia 9-a-fiuoro-
hydrocortisone et a Ia furosémide. Ces résultats montrent one
alteration reversible de l'excrétion urinaire do potassium après
transplantation rénale. L'anomalie de réponse aux minéralo-cor-
ticoIdes suggère que cette alteration est liée a one anomalie do
fonctionnement tubulaire. Le mécanisme de Ia correction par les
thiazides n'est pas conno.
Disorders of renal tubular function following renal
transplantation are being recognized with increasing
frequency. Hyperchloremic acidosis, usually asso-
ciated with renal allograft rejection, has been re-
ported by numerous authors [1—6] with an incidence
in one study as high as 34% in 122 rejection crises [2].
Hyperkalemia, however, has only rarely been re-
ported following renal transplantation [4] and has
received little attention in the literature [7]. We have
been impressed with the high incidence of hyper-
kalemia in our patients following renal transplantation.
The present investigation was undertaken to define
the frequency of this phenomenon and to relate this
to the presence or absence of rejection and the devel-
opment of hyperchloremic acidosis. In addition, four
patients were studied prospectively to determine the
mechanism of the hyperkalemia. The study was de-
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signed to evaluate the responsiveness of the renin-
aldosterone system to appropriate stimuli and to
evaluate the renal tubular response to administration
of mineralocorticoids and other agents known to en-
hance renal potassium excretion.
Methods
Retrospective study. The inpatient and outpatient
records of 75 consecutive patients undergoing renal
transplantation at the Hospital of the University of
Pennsylvania from January, 1973, to June, 1975, were
reviewed for the development of hyperkalemia during
the three-month period immediately following renal
transplantation. Unexplained hyperkalemia was con-
sidered to be present only if the serum potassium
concentration was greater than 5.0 mEq/liter for at
least five consecutive days and could not be attri-
buted to the presence of oliguria, severely impaired
renal function (serum creatinine concentration
greater than 3.0 mg/dl), acidosis (serum bicarbonate
concentration less than 17 mEq/liter or blood pH less
than 7.35 pH U), hemolysis, thrombocytosis, excess
exogenous potassium administration, or potassium-
retaining drugs.
Prospective study. Four patients who developed
hyperkalemia following successful renal trans-
plantation (serum creatinine concentration = 0.9 to
1.4 mg/dl) were studied prospectively at the Clinical
Research Center of the Hospital of the University of
Pennsylvania to determine the mechanism of the hy-
perkalemia. Pertinent laboratory data are given in
Table I and a brief clinical summary of each patient
is given in the appendix.
The study protocol was explained in detail to each
patient, and the studies were performed after in-
formed consent had been obtained.
Blood pH, reticulocyte count, serum haptoglobin,
urine urobilingen, urine hemosiderin, Coomb's test,
total and indirect bilirubin, platelet count, WBC
count, serum glutamic oxaloacetic transaminase, se-
rum glutamine pyruvic transaminase, alkaline
phosphatase, and creatinine phosphokinase were all
within normal limits. In all patients, simultaneous
serum and plasma potassium concentrations were
identical (+0.1 mEq/liter). Other than the test medi-
cations, the only drugs administered during the study
period were azathioprine, prednisone, and antacids.
Determinations of plasma potassium concentra-
tion in five normal subjects before and 30, 60 and 90
mm after the addition of pharmacologic amounts of
methylprednisone and azathioprine in vitro were
identical (+0.2 mEq/liter).
Each subject was allowed to choose his own diet
which he then consumed throughout the study except
as specified below. Serum sodium, potassium, creati-
nine concentrations were determined each morning at
7 A.M. Sequential 24-hr urine collections were ob-
tained from 7 A.M, to 7 A.M. for determination of
sodium, potassium, and creatinine concentrations.
Weights were recorded daily. The study was divided
into four periods.
Period 1. After a period of dietary adjustment, each
subject consumed the basic diet for four days to
ensure constancy of sodium and potassium intake.
On the fourth day, a 24-hr urine collection was ob-
tained for determination of aldosterone excretory
rate. At 7 A.M. of day five, blood for determination
of plasma renin activity and aldosterone concentra-
tions was drawn with the patient in the supine posi-
tion. The patient was then allowed to ambulate for
two hours and blood again drawn for determinations
of plasma renin activity and aldosterone concentra-
tions.
Period 2. The ability to increase aldosterone and
renin secretion was examined after three days of a
low sodium diet (22 mEq/day) in all four patients.
On days five and six, in three patients (patient nos, 2,
3, and 4), 80 mg of furosemide was given orally at 9
A.M. and 7 AM., respectively. A 24-hr urine collec-
tion for determination of aldosterone excretion rate
was begun at 7A.M. on the morning of day seven. At
7 A.M. of day eight, blood was obtained for determi-
nation of supine and stimulated plasma aldosterone
concentration and plasma renin activity. During this
Table 1. Summary of clinical data in four renal transplant patients with hyperkalemia
Onset of Time of
Origin of hyperkalemia, study, days Serum Serum Serum
Patient Etiology of renal days post- post- BUN/Cra Blood HCO3 Cl Na
no. Age, sex renal failure transplant transplant transplant mg/dl pH mEq/liter mEq/lirer mEq/liler
1 34, WF Chronic glom-
erulonephritis
Sister (HLA
identical)
5 9 12/1.0 7.40 22 112 142
2 15, WF Polyarteritis Mother 47 52 42/1.9 7.41 22 108 139
3 40, WM Polycystic kidney
disease Cadaver 7 14 25/1.1 7.42 24 105 142
4 34, WF Chronic pyelone-
phritis and
hypertension Cadaver 11 13 36/1.0 7.39 25 106 140
aAll laboratory values refer to the time of study on the Clinical Research Center.
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period the dietary potassium intake was adjusted to
equal that of period one.
Period 3. The response to exogenous mineralo-
corticoid while on a high sodium intake was exam-
ined during this period. Each patient continued to
consume the basic diet which was supplemented by a
constant amount of sodium ranging from 129 to 175
mEq/day. Each patient received 9-a fluorohydro-
cortisone (Florinef) in a dose of 0.2mg orally on days
nine and ten, 0.6 mg orally on day eleven, and 1 mg
orally per day thereafter until "escape" occurred as
manifested by stabilization of weight and increase in
urinary sodium excretion.
Period 4. Patients consumed the basic diet only
(without supplementation) during this period.
Twenty-four hours after discontinuation of 9-a fluo-
rohydrocortisone, each subject received a combina-
tion of acetazolamide, 0.5 g orally every eight hours,
and sodium bicarbonate, 2.2 g orally every six hours
for four doses. This was followed by the administra-
tion of hydrochlorothiazide, 50mg orally every 12 hr,
for three to four days.
Control studies. Three types of control observa-
tions were obtained. One normal subject (patient no.
7) served as a control to verify the potency of all
medications and was studied under the protocol as
described above. Three of the four hyperkalemic
patients were available for restudy at intervals of 2, 7,
and 15 months following the initial studies and
thereby served as their own controls. At the time of
restudy, the serum potassium concentration was nor-
mal in all three. The ability of the transplanted kid-
ney to increase potassium excretion in response to 9-
a fluorohydrocortisone, 0.2 mg and 1 mg orally, was
evaluated on days four and five, respectively. On day
seven, furosemide, 80 mg orally, was administered at
7 A.M. Daily blood specimens and sequential 24-hr
urine collections were obtained for determinations of
sodium, potassium, and creatinine concentrations.
Two additional normokalemic patients (patient
nos. 5 and 6) were also studied in a fashion similar to
that previously outlined, commencing on the fifth
and seventh day after transplantation.
Analytical methods. Urine and serum sodium and
potassium concentrations were determined by flame
photometry, and urine and serum creatinine concen-
trations were determined by an autoanalyzer [8].
Plasma aldosterone concentration and plasma renin
activity were determined by a modification of radio-
immunoassay techniques as previously described [9].
Results
Retrospective analysis. Unexplained hyperkalemia
developed in 23 of 75(31%) consecutive patients dur-
ing the three month period following renal trans-
plantation. In all 23 patients the serum potassium
concentration had returned to normal in the immedi-
ate posttransplant period and evidence of good renal
function (Scr < 3.0 mg/dl) was present. The average
onset of hyperkalemia was 11 days following trans-
plantation, with a range of 2 to 40 days. The duration
of the hyperkalemia ranged from 5 to 52 days with a
mean of 16 days. Hyperkalemia was moderate in
most cases (5.5 to 6.3 mEq/liter) but occasionally
was severe (7 to 8 mEq/liter), requiring emergency
treatment. There was no correlation between the on-
set of hyperkalemia and rejection as defined by a rise
in the serum creatinine concentration of greater than
20%. In nine patients, the hyperkalemia occurred
without a rise in serum creatinine concentration; and
in seven patients hyperkalemia occurred simultane-
ously with an increase in serum creatinine concentra-
tion; and in seven patients the hyperkalemia pre-
ceeded a rise in serum creatinine concentration by 4
to 15 days (mean = 7). Twelve of the 23 patients had
an associated hyperchloremic acidosis, as defined by
a serum chloride concentration > 108 mEq/liter and
a serum bicarbonate concentration < 22 mEq/liter.
Of the 23 hyperkalemic patients, 11 had received a
cadaveric renal transplant and 12, a kidney from a
living related donor.
Prospective study. All four patients achieved so-
dium and potassium balance within the four to five
day equilibration period (Table 2, Fig. 1). Potassium
balance, however, was achieved only at the expense
of elevated serum potassium concentrations.
Renin-aldosterone axis. These data and normal val-
ues from our laboratory are summarized in Table 3.
The 24-hr urinary aldosterone excretion rate was low
at the end of the equilibration period. Following
sodium depletion with furosemide and a low sodium
diet (mean weight loss = 2.6 0.4 kg), a normal
increase in urinary aldosterone excretion (mean
20.3 + 1.4 g/24 hr) was observed in all four subjects.
The plasma aldosterone concentrations paralleled the
changes in urinary aldosterone excretion. At the end
of the equilibration period, the plasma aldosterone
concentration averaged 8.4 0.6 ng/dl in the supine
position and increased to 15.4 1.9 ng/dl following
sodium depletion. A further increase to 30.0 2.4
ng/dl occurred after two hours of ambulation. Dur-
ing the control period, three patients displayed a
normal rise in plasma renin activity from 0.9 0.1 ng
of angiotensin I generated/mi/hr to 1.8 0.6
ng/ml/hr with a further increase to 2.3 0.15
ng/ml/hr following ambulation. In one patient
(patient no. 1), the plasma renin activity remained
suppressed even after sodium depletion and ambula-
tion for two hours. During the period of low sodium
360 De Fronzo et a!
Table 2. Serum potassium concentration, creatinine clearance, and 24 hr urinary sodium and potassium excretion during the control period
(mean SCM) and following furosemide, 9-a fluorohydrocortisone, sodium bicarbonate plus acetazolamide and hydrochlorothiazide
administration in four hyperkalemic transplant subjects, two normokalemic transplant subjects, and one control subjects
Patient
no. Control'
9-a Fluorohydrocortisone"
Furosemidec Day one After escape
NaHCO3 plus
acetazolamide
l-lydro-
chlorothiazidec
Hyperkalemic transplants
I UNV,mEq/day 110+4 33 66 118
IJKV,mEq/day
Ccr,ml/min
28+2
55 5 NP
21
43 33 NP 41
SK, mEq/literC 5.3 + 0.1 5.0 5.0 5.0(45)
2 UNaV 83+2 283 31 123 188 215
UKV 24 1 49 24 31 63 54
Ccr 35 3 38 39 48 41 34
SKe 5.7 + 0.1 5.1 5.4 6.0 5.2 5.1 (4.6)
3 U,V 128+5 222 80
UKV 60±4 62 54
Ccr 75+2 67 66
SKe 5.4±0.1 5.2 5.1
4 UaV 115±2 203 12 98 266 255
UKV SI + 1 59 49 47 49 62
Cr 61 + 5 75 62 78 79 78S' 5.3 0.1 5.5 5.1
Normokalemic transplants
5.4 5.1 4.9 (4.3)
5 UaV 56 2 306 43 121 180 238
11KV 48 + 2 98 64 83 92 59
Ccr 56 + 5 62 51 48 50 48
Se 4.5 0.1 4.2 4.2 4.1 4.2 4.2
6 UNaV 99+2 312 48
UKV 40+3 77 89
Cr 65+2 62 48
SK" 4.7 0.1 4.3 4.3
Normal control
7 UV 106+6 355 41 21 533 341
UKV 73+4 109 96 101 174 86
Cr 138±5 141 140 149 150 142
SKe 4.1 0.1 4.0 4.0 3.7 3.8 4.1
aAbbreviations: UNV and UKV refer to the 24/hr urinary excretion of sodium and potassium, respectively. Ccr refers to the clearance of
creatinine. SK refers to serum potassium concentration. NP = not performed.
Data for control period refer to mean + SEM during the four-day equilibration period.
Values for furosemide and hydrochlorothiazide refer to the first 24 hr period following drug administration. Parentheses refer to the
serum potassium concentration after four days of hydrochlorothiazide therapy.
d Values for 9-a fluorohydrocortisone refer to the first day of mineralocorticoid administration and the last day when sodium escape was
manifest. The double asterisk (**) means 9-a fluorohydrocortisone was administered for only three days (patient no. 3) and two days (patient
no. 6); study was discontinued at this time because of rejection.
Represents the serum potassium concentration 24 hr after drug administration.
intake, the plasma renin activities were low in all four
subjects.
Response to mineralocorticoids. During the period
of sodium depletion, a significant increase in plasma
aldosterone concentration and urinary aldosterone
excretion occurred. During the first day of 9-a fiuo-
rohydrocortisone administration, potassium excre-
tion (UKV) failed to increase above control values in
any of the four subjects (Table 2). Since urinary
sodium excretion (UNaV) was relatively low at this
time in three of the four subjects, 9-a fluorohydro-
cortisone was continued at a higher dose, awaiting
"escape" until urinary sodium excretion had in-
creased to at least 60 mEq/day. There was no signifi-
cant augmentation of urinary potassium excretion
above control levels in any patient, and all remained
hyperkalemic (SK > 5.1 mEq/liter). All subjects dis-
played a significant sodium retentive response to 9-a
fluorohydrocortisone. In contrast, control subject
(no. 7) exhibited an increase in potassium excretion
on the first day of 9-a fluorohydrocortisone adminis-
tration, and this increase persisted despite a fall in
urinary sodium excretion to 21 mEq/day. Likewise,
in both normokalemic posttransplant patients, a nor-
mal increase in UV was observed following 9-a
fluorohydrocortisone (Table 2).
Response to furosemide, hydrochlorothiazide, and
acetazolamide plus sodium bicarbonate (Table 2). Fu-
rosemide administration resulted in a significant in-
crease in urinary potassium excretion (above control
values) in only one (patient no. 2) of three patients to
whom it was administered. In this patient, UKV rose
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Fig. 1. Summary of metabolic balance data in patient no. I following
Florinef(9-a fluorohydrocortisone), hydrodiuril, and sodium restric-
tion.
from 24 to 49 mEq/day and potassium clearance (CK)
increased from 4.2 to 9.6 mI/mm. A simultaneous fall
in serum potassium concentration from 5.7 to 5.1
mEq/liter occurred concomitantly with the increase
in potassium excretion. In all three subjects UNaV
rose significantly following furosemide administra-
tion.
Acetazolamide-sodium bicarbonate administration
resulted in an increase in potassium excretion in one
of the two subjects to whom it was given. In patient
no. 2, who also responded to furosemide, UKV rose
from 24 to 63 mEq/day and CK from 4.2 to 12.1
mI/mm with a concomitant fall in serum potassium
concentration to 5.2 mEq/liter. No change in potas-
sium excretion occurred in patient no. 4.
A consistent increase in potassium excretion oc-
curred following hydrochiorothiazide administration
in all three subjects. This augmentation of potassium
excretion was observed on the first day of hydro-
chlorothiazide therapy and persisted throughout its
administration. In all three subjects serum potassium
concentration fell dramatically to less than 5.0
mEq/liter (mean 4.5 + 0.1 mEq/liter) and re-
mained in the normal range throughout the period of
hydrochlorothiazide administration. In subject no. 1,
hydrochlorothiazide was stopped after five days. This
was followed by a prompt fall in UKV and i return of
hyperkalemia (Fig. 1). Reinstitution of hydro-
chlorothiazide five days later reversed these abnor-
malities.
In control subject no. 7, a rise in UKV occurred
following furosemide (73 to 109 mEq/day) acetazola-
mide-sodium bicarbonate (174 mEq/day), and hy-
drochlorothiazide (86 mEq/day) administration.
In both normokalemic transplant patients, UKV
rose normally following furosemide, from 48 to 98
mEq/day in patient no. 5 and from 40 to 77 mEq/day
in patient no. 6. In patient no. 5, a rise in UKY also
occurred following acetazolamide-sodium bicarbo-
nate (92 mEq/day) and hydrochlorothiazide (59
m Eq/day).
Re-evaluation of urinary potassium excretion. The
response to furosemide and 9-a fluorohydrocortisone
in patients 1 through 3, when these patients were
restudied 15, 7, and 2 months after the initial study, is
shown in Table 4. The serum potassium concentra-
tion was normal (4.1 to 4.5 mEq/liter) in all three at
the time of restudy. In contrast to the previous study,
9-a fluorohydrocortisone administration resulted in a
prompt increase in potassium excretion from a mean
control value of 52 + 9 to 87 + 12 mEq/day. Potas-
sium clearance increased from 11.2 + 2.2 to 20.0 + 3.2
mI/mm. In direct contrast to results obtained earlier,
furosemide increased potassium excretion in the three
subjects to 113 + 3 mEq/day. This was associated
with a concomitant rise in sodium excretion from 150
+ 26 to 429 90 mEq/day.
Table 3. Summary of plasma aldosterone and renin responses and 24-hr urinary aldosterone excretion rate in four renal transplant patients
and one control subject (patient no. 7) before and after sodium depletion.
.Patient
no.
. .Position
of patient
Pasma renin
ng angiotensin I
generated/mi/hr
Plasm a aldosterone
ng/dl
Urinary aldosterone
excretion rate
/2g/24 hr
—______________________________
Control Low Na diet Control Low Na diet Control Low Na diet
I Supine
Erect
0.10 0.15
0.25 0.40
8.0
17.0
20.0
34.0
3.2 16.8
2 Supine
Erect
1.0 2.2
1.6 2.6
10.1
23.0
15.9
23.4
5.7 22.0
3 Supine
Erect
0.7 1.1
— 2.1
8.2
—
14.6
33.1
<1.0 22.8
4 Supine
Erect
1.0 2.0
1.5 2.2
7.1
12.2
11.0
29.5
1.4 19.4
7 Supine
Erect
0.15 —
0.64 3.4
5.5
11.6
—
37.6
9.8 26.2
Normal values Supine 0.6 + 0.2 4.6 + 1.2 6.0 1.1 14.1 + 5.0 >10
(mean + sEM) Erect 1.7 + 0.2 10.8 + 2.3 9.4 + 1.9 23.1 + 3.9
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Table 4. Twenty-four-hour urinary sodium and potassium excretion
in three patients restudied when serum potassium concentration
had returned to normals
Patie
no.
nt
Control5
9-a fluorohy-
drocortisone Furosemide
I UNV,fl'ZEq/dy 140± 5 15 303
UV,mEq/da.y 37±2 68 119
Car, mI/mm 85 + 1 87 82
Serum K,
mEq/Iifer' 4.8 + 0.1 4.4 3.1
2 UNaV 112±4 86 603
UV 49±5 82 lii
Ccr 60±2 64 62
Serum K 4.7 + 0.1 4.5 4.3
3 U.jaV 199 + 7 104 382
UKV 69±7 110 110
Ccr 59±3 60 63
SerumK 4.5±0.1 4.2 4.1
aAbbreviations: UNaV and UKV refer to 24-hr urinary excretion of
sodium and potassium, respectively. Cr refers to the clearance of
creatinine.
5Refers to the mean + SEM of the three-day equilibration period.
cRepresents the serum potassium concentration 24 hr after drug
administration.
Discussion
Our initial data, based upon retrospective chart
analyses, suggested that significant hyperkalemia was
a common event following renal transplantation.
Hyperkalemia, which could not be attributed to oh-
guria, reduced glomerular filtration rate, or increased ex-
ogenous potassium intake, occurred in 23 of 75 con-
secutive renal transplant recipients. There was no
apparent relationship between the development of
hyperkalemia and either hyperchloremic acidosis or
the onset of graft rejection. In animal studies [10, 11]
it has been demonstrated that 50 to 75% ablation of
renal mass does not result in hyperkalemia. Similarly,
the serum potassium concentration and potassium
clearances before and one to two weeks after unilat-
eral nephrectomy in renal transplant donors have
been reported to be the same [12]. Thus, the hyper-
kalemia observed in our transplant recipients does not
appear to be explainable by an acute reduction in
renal cell mass. To further define the mechanisms
contributing to the development of hyperkalemia fol-
lowing renal transplantation, four such patients and
two normokalemic patients were studied on a meta-
bolic ward. None of these patients had oliguria, de-
creased glomerular filtration rates, hemolysis, throm-
bocytosis, or significant acidosis as a cause of the
hyperkalemia observed.
Many factors have been shown to alter the rate of
urinary potassium excretion. Important among them
are delivery of sodium to the potassium secretory
sites, the level of mineralocorticoids present, the pres-
ence of large amounts of poorly reabsorbable anions,
such as bicarbonate, at the potassium secretory sites,
and the administration of diuretics.
Many studies have shown that decreased sodium
excretion is frequently accompanied by low rates of
potassium excretion. In our patients, sodium excre-
tion ranged between 83 and 128 mEq per day during
the control period, but potassium excretion was in-
sufficient to correct hyperkalemia. Similarly, during
the period of mineralocorticoid "escape," sodium ex-
cretion exceeded 60 mEq per day in the presence of
pharmacologic doses of 9-a fluorohydrocortisone;
yet urinary potassium excretion remained low. The
patients exhibited no signs of either increased or de-
creased total body sodium; thus it seems unlikely that
the defect in potassium excretion was related to alter-
ations in tubular sodium transport.
The responsiveness of the renin-angiotensin-al-
dosterone system was evaluated by restriction of so-
dium intake and administration of furosemide to pro-
duce sodium depletion and extracellular fluid volume
contraction. This maneuver produced a normal in-
crease in both urinary aldosterone excretion and
plasma aldosterone concentration. These normal re-
sponses are similar to those reported by other in-
vestigators [13—15], Although plasma renin activity
increased normally following ambulation, a sub-
maximal increase was observed in all patients follow-
ing sodium depletion. This is in contrast to previously
published data in normokalemic renal transplant
patients [13]. Nonetheless, a normal rise in plasma
aldosterone concentration was observed without a
change in plasma potassium concentration. It is pos-
sible that the normal aldosterone response and
blunted plasma renin response were related to the
elevated level of serum potassium [16].
The renal responsiveness to mineralocorticoids was
evaluated with the administration of pharmacologic
doses of 9-a fluorohydrocortisone. In each subject,
with continued administration, urinary sodium excre-
tion exceeded 60 mEq per day, ensuring adequate
distal nephron sodium delivery. Yet none of the
patients had a significant increase in urinary potas-
sium excretion. Thus, our patients displayed a nor-
mal increase in aldosterone secretion with phys-
iologic stimulation (i.e., sodium depletion) but failed
to augment potassium excretion in response to miner-
alocorticoid administration. Despite the failure to
increase potassium excretion, there was a significant
reduction in sodium excretion observed with miner-
alocorticoid administration. These data thus suggest
the presence of a specific defect in tubular potassium
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transport, most likely, a defect in tubular potassium
secretion, rather than non-specific unresponsiveness
to mineralocorticoids.
Three subjects were restudied at a later date when
serum potassium concentration had returned to nor-
mal. At this time, urinary potassium excretion re-
sponded appropriately to mineralocorticoid adminis-
tration, indicating that the defect in the renal
handling of potassium, previously apparent in these
patients, was spontaneously reversible.
We further evaluated the responsiveness of these
patients to other stimuli known to augment potas-
sium excretion, presumably, by enhancing potassium
secretion. Two of three patients had no kaliuretic
response to furosemide, and one of the patients had
no kaliuretic response to acetazolamide-sodium bi-
carbonate infusion. In direct contrast to the lack of
response to mineralocorticoid administration and the
equivocal response to furosemide, acetazolamide,
and sodium bicarbonate, the administration of hy-
drochiorothiazide had a dramatic effect. Urinary po-
tassium excretion was increased, and serum potas-
sium concentration fell to normal within three to four
days in each of the three subjects given hydro-
chiorothiazide. Discontinuation of hydrochlorothi-
azide resulted in a fall in urinary potassium excretion
and the return of hyperkalemia.
Thus, the data indicate that hyperkalemia follow-
ing renal transplantation can be observed in the ab-
sence of acidosis, renal insufficiency, or overt rejec-
tion. Normal plasma and urinary aldosterone
concentrations suggest that the defect does not reside
in the renin-angiotensin system. The hyperkalemia
appears to be secondary to a defect in the renal
handling of potassium, characterized by an inability
to augment potassium secretion normally in response
to mineralocorticoids. The defect is spontaneously
reversible and appears to be responsive to the admin-
istration of thiazides. A similar type of defect in
tubular potassium secretion in the absence of renal
insufficiency and in the presence of normal aldoste-
rone secretion has been previously reported [17—20].
Three of these four patients were children, and the
fourth was a patient with systemic lupus erythema-
tosus. It is noteworthy that in three of these patients
who received thiazides, a prompt increase in urinary
potassium excretion was observed with correction of
hyperkalemia [17—19]. The exact site of the defect in
potassium secretion and the mechanism by which it is
corrected by thiazide administration remain unclear.
Current concepts indicate that potassium secretion in
the distal nephron is a function of both sodium trans-
port and intracellular potassium concentration [21].
The lack of response to mineralocorticoid adminis-
tration, despite adequate sodium delivery to the distal
nephron and accelerated sodium reabsorption, sug-
gests that the defect resides either in cellular uptake at
the antiluminal membrane or in a selective decrease
in permeability to potassium at the luminal side.
Thiazides may be effective by altering either cellular
potassium uptake or membrane permeability. It
should be pointed out that it is not possible to elimi-
nate the possibility that thiazides may also have extra
renal effects upon potassium distribution which may
have contributed to the decrease in serum potassium
observed in these patients.
The relationship between these observations and
renal transplantation also remains unclear. Our data
demonstrate that hyperkalemia is a frequent occur-
rence following transplantation, but the defect does
not seem to be related to graft rejection as reflected in
changes in serum creatinine concentration. In only 7
of the 23 patients examined retrospectively could the
hyperkalemia be temporally related to a rise in serum
creatinine, and in none of the four patients studied in
detail was the hyperkalemia associated with a rise in
serum creatinine or a fall in creatinine clearance.
However, this does not exclude the possibility that
the hyperkalemia is a manifestation of renal tubular
rejections. In support of this concept is the recent
demonstration of antitubular basement membrane
antibodies in renal transplant patients [22,23]. None
of the patients reported here were biopsied at a time
when they were hyperkalemic, and there are no prior
studies which have attempted to correlate tubular
dysfunction with renal histopathology.
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Appendix
Patient 1. Seventeen years prior to renal trans-
plantation, this 34-yr-old white female was evaluated
for hypertension and albuminuria with a normal
blood urea nitrogen of 12 mg/dl. At that time, a renal
biopsy was reported to have shown chronic glomer-
ulonephritis. Her course was one of slowly progres-
sive renal insufficiency. Hyperkalemia was not noted
until the serum creatinine level reached 11.0 mg/dl.
At that time her serum electrolytes revealed a sodium
concentration of 136 mEq/liter; potassium, 5.1
mEq/liter; chloride, 98 mEq/liter; and bicarbonate,
10 mEq/liter. With the onset of uremic symptoms,
she was treated with one peritoneal dialysis, and on
January 31, 1973, she received an HLA identical
renal transplant from her sister. By the fourth post-
transplant day, the serum creatinine concentration
had fallen to 1.0 mg/dl, and the serum potassium
concentration was 4.4 mEq/liter. The serum potas-
sium then rose to 5.5 mEq/liter and leveled off at 5.2
to 5,3 mEq/liter. On the ninth postoperative day, she
was transferred to the Clinical Research Center for
further study. At this time, medications included
prednisone, 80 mg/day, and azathioprine, 50
mg/day.
Patient 2. This 15-yr-old white female presented
with a six month's history of fatigue, anorexia, and
hypertension and was found to have the nephrotic
syndrome with a creatinine clearance of 10 mi/mm.
The serum sodium concentration was 1 38 mEq/liter;
potassium, 4.5 mEq/liter; chloride, 105 mEq/liter;
and bicarbonate, 14 mEq/liter. Collagen-vascular
disease workup was negative. Antiglomerular base-
ment antibodies were absent and the serum com-
plement was normal. A renal biopsy revealed a pro-
liferative glomerulonephritis with advanced sclerosis
and crescent formation and a necrotizing fibrinoid
vasculitis of all small and medium sized vessels, con-
sistent with a diagnosis of polyarteritis nodosa. After
four peritoneal dialyses, she received a renal allograft
from her mother on September 6, 1974. Following
transplantation, the serum creatinine concentration
promptly fell to 0.8 mg/dl. On the twenty-first post-
operative day, she experienced a moderately severe
rejection with the serum creatinine concentration ris-
ing to 8.9 mI/di. She was treated with iv. methyl-
prednisolone, and the serum creatinine concentra-
tion gradually fell to 3.2 mg/dl. The serum potassium
concentration which had remained normal through-
out her course, including the period of rejection, rose
to 5.5 mEq/liter on the forty-seventh postoperative
day and remained between 5.8 to 6.2 mEq/liter. The
serum creatinine concentration at this time was 1.9
mg/dl. She was transferred to the Clinical Research
Center for further evaluation of her hyperkalemia on
the fifty-second postoperative day. Her medications
were prednisone, 35 mg/day, and basaljel. Azathio-
prine had been discontinued because of leukopenia.
Patient 3. This 40-yr-old white male was first eval-
uated three years prior for headaches and hyperten-
sion. He was documented to have polycystic kidney
disease, demonstrated by renal arteriogram. Renal
function progressively deteriorated over the sub-
sequent three years, and he was begun on hemo-
dialysis. Urine volume remained substantial despite
severe renal insufficiency, and hyperkalemia was ab-
sent until the serum creatinine level reached 19.2
mg/dl. At this time, serum electrolytes revealed a
sodium concentration of 135 mEq/liter; potassium,
5.3 mEq/liter chloride, 100 mEq/liter; and bicarbo-
nate, 13 mEq/liter. He received a cadaveric renal
transplant on February 27, 1975, without nephrec-
tomy. Postoperatively there was a brief diuretic phase
during which the serum creatinine concentration fell
to 1.8 mg/dl and the serum potassium level to 3.9
mEq/liter. On the seventh postoperative day, the se-
rum creatinine concentration was 1.5 mg/dl, but the
serum potassium level had risen to 5.1 mEq/liter. The
serum potassium concentration rose further to 6.2
mEq/liter and stabilized between 5.6 and 6.0
mEq/liter. On the fourteenth postoperative day, he
was transferred to the Clinical Research Center for
evaluation of the hyperkalemia. At the time of study,
his medications included basaijel, prednisone, 50
mg/day, and azathioprine, which had been decreased
to 20 mg/day because of leukopenia.
Patient 4. This 34-yr-old white female developed
bilateral pyelonephritis and hypertension during her
eighth pregnancy, eight years prior to the present
study. Subsequently, she experienced multiple bouts
of pyelonephritis and poorly controlled hypertension.
Elevation of the serum creatinine was first noted four
years prior to this study, and over the ensuing three
years, renal function decreased progressively, necessi-
tating the institution of hemodialysis. Because of re-
current urinary tract infections and refractory hyper-
tension, bilateral nephrectomy was performed.
Although a hyperchloremic acidosis was present ear-
lier in her course, hyperkalemia was not noted until
the serum creatinine level had reached 10.9 mg/dl.
On March 27, 1974, she received a cadaveric renal
transplant. No diuresis was observed during the first
postoperative week, and the serum creatinine concen-
tration remained elevated to the 5.2 to 8.9 mg/dl
range. The serum potassium concentration, however,
remained within normal limits, ranging from 3.1 to
4.0 mEq/liter. During the second postoperative
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week, the serum creatinine fell to 1.0 mg/dl and
remained at this level throughout the remainder of
her hospital stay. On the eleventh postoperative day,
the serum potassium concentration had risen to 6.3
mEq/liter, and despite sodium polystyrene sulfonate
(Kayexalate) therapy, rose further to 6.8 mEq/liter
on the following day with concomitant electro-
cardiographic changes. On the thirteenth post-
operative day she was transferred to the Clinical Re-
search Center for study of her hyperkalemia. At that
time, her medications included prednisone, 50
mg/day, and azathioprine, 37.5 mg/day.
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